Contact Us | Print Page | Sign In | Register
News & Press: Industry News for MS (INforMS)

CMSC INforMS: Sodium Intake And Its Association With Multiple Sclerosis Progression

Tuesday, June 13, 2017  
Posted by: Elizabeth Porco
Share |

HealthDay News — There is no association between average 24-hour urine sodium levels and conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (MS), according to a study published in the Annals of Neurology.

Kathryn C. Fitzgerald, ScD, from the Johns Hopkins School of Medicine in Baltimore, and colleagues examined whether a high-salt diet is associated with faster conversion from CIS to MS. A total of 465 patients with CIS provided a median of 14 spot urine samples during 5-year follow-up of the BENEFIT trial.

The researchers observed no correlation between average 24-hour urine sodium levels and conversion to clinically definite MS over the 5-year follow-up (hazard ratio [HR] 0.91; 95% CI, 0.67-1.24 per 1 g increase in estimated daily sodium intake). There were also no associations with clinical or magnetic resonance imaging (MRI) outcomes (new active lesions after 6 months: HR 1.05 [95% CI, 0.97-1.13]; relative change in T2 lesion volume: −0.11 [95% CI, −0.25-0.04]; change in Expanded Disability Status Scale: −0.01 [95% CI, −0.09-0.08]; relapse rate: HR 0.78 [95% CI, 0.56-1.07]). In categorical analyses using quintiles, the results were similar.

"Our results, based on multiple assessments of urine sodium excretion over 5 years and standardized clinical and MRI follow-up, suggest that salt intake does not influence MS disease course or activity," the authors wrote.

Disclosure: One author is an employee of Bayer AG.


Fitzgerald KC, Munger KL, Hartung HP, et al. Sodium intake and multiple sclerosis activity and progression in BENEFIT [published online May 26, 2017]. Ann Neurol. doi:10.1002/ana.24965

Neurology Advisor

CMSC Disclaimer 
The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275